- Savara Inc at Guggenheim Healthcare Talks Biotechnology Conference TranscriptFeb 07, 2024
- Savara Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Savara Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) TranscriptSep 20, 2021
- Savara Inc Annual Shareholders Meeting TranscriptJun 10, 2021
- Q2 2020 Savara Inc Earnings Call TranscriptAug 06, 2020$2.04 (-3.77%)Earnings
- Savara Inc Annual Shareholders Meeting TranscriptMay 27, 2020
- Q1 2020 Savara Inc Earnings Call TranscriptMay 07, 2020$2.55 (+5.81%)Earnings
- Savara Inc. - Special Call TranscriptApr 03, 2020
- Q4 2019 Savara Inc Earnings Call TranscriptMar 12, 2020$2.55 (+8.05%)Earnings
- Q3 2019 Savara Inc Earnings Call TranscriptNov 07, 2019$0.91 (-1.09%)Earnings
- Q2 2019 Savara Inc Earnings Call TranscriptAug 08, 2019$2.51 (+2.03%)Earnings
- Savara Inc Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP) TranscriptJun 12, 2019
- Q1 2019 Savara Inc Earnings Call TranscriptMay 09, 2019$10.72 (-2.46%)Earnings
- Q4 2018 Savara Inc Earnings Call TranscriptMar 13, 2019$8.6 (+1.30%)Earnings
Savara Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Great, okay. Hi, everyone. Thanks for joining today. My name is Frank Brisebois. I am a senior biotech analyst here at Oppenheimer. It is my pleasure to introduce Savara today. From the Company, we have the Chair and CEO, Matt Pauls and CMO, Badrul Chowdhury to present. Savara is an orphan lung disease company, and its lead program is molgramostim which is in Phase 3 development for aPAP. I will let them explain what aPAP is and how to say it, because I get it wrong most times. We currently cover the stock with an outperform rating and a $5 price target.
In terms of format here, what we'll do is we'll do a fireside chat discussion. Feel free to send any questions in the Q&A tab. I think it's at the bottom of your screen. I'll do my best to get to them. If not, you can email me as well.
So with that, thank you very much, Matt and Badrul, for joining. And maybe, Matt, if you can just start us off with a quick overview of the Company.
Sure.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)